A5089778133- Hepatocellular Carcinoma Treatment and Prognosis
- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- MRI in cancer diagnosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
Tongji University
2023
Peking University
2022
Peking University Cancer Hospital
2022
Abstract Background Due to the heterogeneity of low‐grade gliomas (LGGs), lack randomized control trials, and strong clinical evidence, effect extent resection (EOR) is currently controversial. Aim To determine best choice between subtotal (STR) gross‐total (GTR) for individual patients identify features that are potentially relevant treatment heterogeneity. Methods Patients were enrolled from SEER database. We used a novel DL approach make recommendations with LGG. also made causal...
Hepatobiliary cancers are primarily categorized into hepatocellular carcinoma (HCC) and biliary tract (BTC). HCC is one of the most common malignant cancers, with increasing global incidence. Immune checkpoint inhibitors (ICIs) have changed approach management in recent years. The combination atezolizumab bevacizumab has surpassed sorafenib as standard regimen for first-line treatment advanced unresectable HCC. However, optimal choice second-line after initial ICIs lacks clinical trial...